Key takeaways
- Loren Pickart and M. M. Thaler reported the tripeptide from human serum in 1973; it was identified as glycyl-histidyl-lysine in 1977, and its copper binding was described in 1980–1982.
- Its names run from GHL and GHK to GHK-Cu, the cosmetic name copper tripeptide-1, and drug-development names: prezatide copper acetate, PC-1020 and Iamin.
- Of 105 PubMed records naming GHK-Cu, 70 appeared after 2019 (our count); a 2026 review found about 35% of the primary literature it included lists Pickart or Margolina as authors.
- In 2018 an industry-funded cosmetic panel, not a regulator, assessed copper tripeptide-1 (GHK-Cu’s cosmetic name) for cosmetic use only, at use concentrations in the parts-per-million range.
- FDA’s list of 14 May 2026 puts GHK-Cu, except injectable routes, back in Category 1, “bulk drug substances under evaluation”, and FDA plans to consult its advisory committee before the end of February 2027; for injectable GHK-Cu, FDA cites possible immune reactions. No medicine containing it appears in Drugs@FDA.
01GHK-Cu history at a glance
A dated record, from the first paper to November 2026.
| Date | What happened |
|---|---|
| May 1973 | Loren Pickart and M. M. Thaler report a tripeptide from human serum in experiments with liver cells (Nature New Biology). A synthetic version is reported in September. |
| 1977 | The tripeptide is identified as glycyl-histidyl-lysine. |
| 1980 | Two papers report that it travels with copper and iron in plasma and binds copper(II); one proposes that it may act as a copper transport factor. |
| 1982 | Spectroscopy describes the copper complex in solution: one copper(II) per peptide, bound in part through histidine. |
| 1988 | A fibroblast-culture study from Reims, co-authored by Pickart, is the earliest record in our PubMed search for the copper complex’s names. |
| 1991 | A report co-authored by Pickart lists ProCyte Corporation, Kirkland, Washington, as an author affiliation. |
| 1998–2016 | Small cosmetic skin studies, mostly conference posters; in 2006, one PubMed-indexed randomised trial of a skin-care regimen, which found no objective difference. |
| Nov 2018 | The Cosmetic Ingredient Review, an industry-funded panel and not a regulator, publishes its assessment of tripeptide-1 and its metal salts, including copper tripeptide-1, for cosmetic use only. |
| Nov 2020 | The first of three firm-initiated US recalls of products listing GHK-Cu, for lack of assurance of sterility. The second follows in July 2025. |
| 13 Apr 2026 | The TGA names products containing GHK-Cu among its examples of unapproved peptide products, “often supplied in injectable form”. |
| Apr 2026 | FDA’s advisory committee page (content current 15 April 2026) lists GHK-Cu for a meeting “before the end of February 2027” on the 503A bulks list. |
| 22 Apr 2026 | FDA removes GHK-Cu (except injectable routes) from Category 1 of its compounding policies, because the nominations were withdrawn. |
| May 2026 | A nominator clarifies on 5 May that it withdrew only the injectable route; FDA’s list of 14 May puts GHK-Cu (except injectable routes) back in Category 1. |
| Oct 2026 | A third firm-initiated recall, for lack of processing controls. |
| Nov 2026 | No medicine containing it appears in Drugs@FDA. It is not named on WADA’s 2026 or 2027 Prohibited List; WADA says a peptide not named on the List “may still be prohibited”, and anti-doping organisations decide how class S0 applies. |
02How was GHK discovered?
The earliest papers we found on GHK in PubMed date from 1973. In Nature New Biology that May, Loren Pickart and M. M. Thaler reported a tripeptide in human serum, in experiments with liver cells that included a liver tumour (hepatoma) cell line. A paper in September of the same year reported a synthetic version. These were laboratory studies on cells (T4), not studies in people.
Pickart’s own account, in a 2018 review he co-wrote, describes the experiment that led to it: human plasma added to liver tissue changed the proteins the tissue made. That is the discoverer’s account. A 2026 systematic review notes that Pickart “held commercial interests in the field for decades”.
The structure came next. A 1977 paper identified the tripeptide as glycyl-histidyl-lysine. In 1980, Pickart and colleagues reported that it travels with roughly equal amounts of copper in plasma, forms complexes with copper(II), and may act as a copper transport factor. A 1982 spectroscopy study described the complex in solution as one copper(II) ion per peptide, bound in part through the histidine.
03What is GHK-Cu’s structure?
- The peptide. GHK is three amino acids: glycine, histidine and lysine. PubChem gives its mass as 340.38 g/mol.
- The copper complex. GHK-Cu is GHK bound to copper(II), one to one. A 2026 independent review describes the binding through the histidine ring, the peptide backbone and the amino end.
- Salt forms. PubChem holds separate records for the complex (prezatide copper) and for prezatide copper acetate.
The copper is what makes the powder and solutions blue: why is GHK-Cu blue? A close relative, AHK-Cu, differs by one amino acid and is a different peptide: AHK-Cu vs GHK-Cu.
04How did GHK-Cu get its names?
From description to letters. The 1973 paper spoke of a “tripeptide in human serum”. After the 1977 identification, early papers abbreviated it GHL, from glycyl-L-histidyl-L-lysine. By 1988, papers used GHK, the one-letter codes for the same three amino acids (K is lysine), and GHK-Cu for the copper complex.
Cosmetic names. In ingredient lists the complex is copper tripeptide-1, and GHK on its own is tripeptide-1. The same family includes palmitoyl tripeptide-1, GHK with a fatty-acid chain and no copper.
Drug-development names. PubChem lists “Iamin” and the code PC-1020 among the synonyms of prezatide copper acetate, along with international non-proprietary name forms such as prezatidi cuprici acetas. No medicine under any of these names appears in Drugs@FDA.
05How did research on GHK-Cu develop?
Slowly for decades, then fast. Two-thirds of the PubMed records that name the copper complex appeared after 2019 (our count).
| Years | PubMed records naming GHK-Cu |
|---|---|
| 1988–1989 | 1 |
| 1990–1999 | 5 |
| 2000–2009 | 10 |
| 2010–2019 | 19 |
| 2020–18 Nov 2026 | 70 |
| All years | 105 |
Our count from a PubMed title and abstract search for GHK-Cu, its spelling variants, copper tripeptide-1 and prezatide, by publication date, run 18 November 2026. Older papers that say glycyl-histidyl-lysine or GHL without these names are not counted.
1970s–1980s: plasma and cells. The earliest papers we found came from Pickart and Thaler, on plasma chemistry and cultured liver cells. From 1988 a group in Reims, France, ran fibroblast and wound-model studies, some with Pickart. These are cell and animal studies (T4, T3).
1990s: a company and a drug name. A 1991 report co-authored by Pickart lists ProCyte Corporation, Kirkland, Washington, as an author affiliation. PubChem records a drug name, prezatide copper acetate, with international non-proprietary name forms. No medicine containing GHK-Cu appears in Drugs@FDA.
1998–2016: cosmetics. The human studies of this period applied it to the skin. Most were small, short cosmetic studies reported as conference posters, known mainly through a 2018 review by Pickart and Anna Margolina. The one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing, had 13 completers; computer analysis and blinded evaluators found no significant difference, though patients rated their skin higher. Detail: topical GHK-Cu.
2020s: growth, and independent reviews. A 2026 systematic review found that about 35% of the GHK-Cu primary literature it included lists Pickart or Margolina of Skin Biology Inc. as authors, and called the human literature “thin and fragmented”. A 2026 evidence-map review, whose authors declare no conflicts, wrote that GHK-Cu’s clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”. ClinicalTrials.gov lists four studies that apply a product containing GHK-Cu to skin, none with posted results, and we found no controlled trial of injected GHK-Cu (18 November 2026). The evidence today: GHK-Cu research guide.
06How have regulators treated GHK-Cu?
Two tracks: a cosmetic ingredient, and a substance that regulators have started to name as an unapproved peptide product.
As a cosmetic. FDA says “cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market”, and that whether a product is a cosmetic or a drug “is determined by a product’s intended use”. In 2018 the Cosmetic Ingredient Review, which the cosmetics industry’s trade association set up and funds and which describes its process as independent, assessed tripeptide-1, its metal salts and related ingredients. It noted that copper tripeptide-1 is used in cosmetic products and reached a conclusion it limited to “the present practices of use and concentration described in this safety assessment”, in which typical use concentrations were in the parts-per-million range. The conclusion covers cosmetic use only. More: peptides in skincare.
In US compounding. FDA’s compounding page (content current 22 April 2026) lists GHK-Cu for injectable routes among substances previously in Category 2 whose nominations were withdrawn, noting that compounded injectable drugs containing it “may pose risk for immunogenicity” and that “there are limited data in humans”. For other routes, FDA’s list of 14 May 2026 records that GHK-Cu was removed from Category 1 on 22 April 2026, then added back to Category 1, “bulk drug substances under evaluation”, after a nominator clarified on 5 May. FDA “intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027” on listing it. FDA describes the committee as making “non-binding recommendations”.
Recalls. FDA’s enforcement data hold three firm-initiated Class II recalls of products listing GHK-Cu: two for lack of assurance of sterility (initiated November 2020 and July 2025) and one for lack of processing controls (October 2026).
Australia and sport. The TGA’s April 2026 advisory names products containing GHK-Cu among its examples of unapproved peptide products, “often supplied in injectable form”. GHK-Cu is not named on WADA’s 2026 or 2027 Prohibited List; class S0 covers pharmacological substances with no current government approval for human therapeutic use, WADA says a peptide not named on the List “may still be prohibited”, and anti-doping organisations decide how it applies.
07What we don’t know about GHK-Cu’s history
- Why prezatide copper acetate, which has international non-proprietary name forms, appears nowhere in Drugs@FDA. We found no statement explaining it.
- How much of the GHK-Cu literature independent groups have repeated. A 2026 systematic review wrote that “the concentration of authorship in a small number of investigators limits the independence of the evidence base”.
- What FDA’s advisory committee will recommend, and when. No Federal Register notice for the meeting had appeared by 18 November 2026.
- The discovery story beyond the discoverer’s own account. The 1973 papers are indexed without abstracts, and we read them only through their records and later reviews.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.